Misprint Prompts Tablet Recall

Dr. Reddy’s Laboratories Inc. is recalling more than 73,000 bottles of glimepiride tablets because of a misprint on the tablets. The recall was published in the February 14, 2024, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects glimepiride tablets, 1 mg, in 100-count bottles (NDC 55111-320-01) from lots T2303622, T2303626, T2303627, T2303628, and T2303629 (Exp. 6/26). Also included in the recall are glimepiride tablets, 1 mg, in 500-count bottles (NDC 55111-320-05) from lots T2303609 and T2303610 (Exp. 6/26). The tablets were manufactured by Dr. Reddy’s Laboratories Limited, Srikakulam, India, and were distributed throughout the United States.

Dr. Reddy’s Laboratories voluntarily initiated the recall January 18, 2024. The FDA designated the recall Class III on February 6, 2024. Per the recall classification, use of the affected tablets is not likely to cause harm.

Glimepiride is a prescription drug indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.